• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Lebid L. V., Kireev I. V., Ljashenko A. A.


    About the author: Lebid L. V., Kireev I. V., Ljashenko A. A.
    Type of article Scentific article
    Annotation Tuberculosis is still one of the main public health problem worldwide. Various studies of single nucleotide polymorphism (SNP) of arylamine N-acetyltransferase 2 (NAT2) in tuberculosis patients in different populations are carried out to determine the probability of developing the disease and metabolic features of anti-TB drugs. It is relevant to using the SNP to predict not only the possibility of developing the disease beforehand, but also to predict the severity and characteristics of its course, than is necessary for effective treatment. Objective. To study the genetic polymorphism of NAT2 in patients with pulmonary tuberculosis in the Kharkov region, Ukraine 5 SNPs of NAT2 were determined including C282T, C481T, G590A, A803G and G857A. Materials and methods. The research group consisted of 27 Caucasians with different types and prevalence of tuberculosis process, with different sensitivity of Mycobacterium tuberculosis to anti-TB drugs and different treatment efficacy. The molecular genetic study was carried out using a set of reagents for DNA extraction Diatom ™ DNA Prep 200 according to the manufacturer's instructions. Statistical analysis of the results of research carried out using SPSS 22. Results and discussion. The group surveyed included 27 patients, unrelated individuals, Caucasians: 22 men and 5 women. In 19 patients was installed newly diagnosed pulmonary tuberculosis. One patient had recurrent pulmonary tuberculosis. In 7 patients - chemoresistant pulmonary tuberculosis: from 5 - multidrug-resistant tuberculosis (MDR-TB) and 2 - with enhanced resistance tuberculosis (XDR-TB). All 27 patients were found the same combination of mutations 282C / T, 481C / T, 590G / A, in which were found only heterozygotes, whereas among genotypes A803G, G857A were met both heterozygotes and homozygotes. Significant differences were obtained only for genotype A803G. Revealed that all patients with "wild" type 803A (100%) had extensive tuberculosis with the defeat of both lungs, whereas heterozygotes A803G in 54.5% of cases had the process limited in one lung, the mutant homozygotes 803GG - 50% of cases (p <0, 05). All patients homozygotes as a "wild" type 803A, and the mutated 803 GG were smear positive. Heterozygotes A803G were smear positive in 36.4% (p <0,05). Comparative analysis of the effectiveness of treatment in patients with sensitive Mycobacterium tuberculosis, MDR-TB and XDR-TB with different genetic polymorphism NAT2 has not set significant differences. Conclusions:1. In the Caucasian population of Kharkiv region, Ukraine there is no association of polymorphic variants C282T, S481T, G590A and G857A gene NAT2 with clinical manifestations of pulmonary tuberculosis. 2. "Wild" type 803A is associated with a predisposition to severe extensive forms of the smear positive tuberculosis.
    Tags pulmonary tuberculosis, NAT2, gene polymorphism
    • Apt A. S. Geneticheskie aspekty vyjavlenija grupp riska po tuberkulezu / A. S. Apt // Problemy tuberkuleza. – 2001. – N 7. – S. 65–68.
    • Antonenko P. B. Polіmorfіzm genotipu N–acetiltransferazi 2 sered hvorih na tuberkul'oz / P.B. Antonenko, V.J. Kresjun // Vіsnik Vіnnic'kogo nacіonal'nogo medichnogo unіversitetu. – 2013.- № 1(T.17).- S. 51-55.
    • Kondakova M. N. Kliniko-geneticheskie osobennosti patogeneza tuberkuleza organov dyhanija u podrostkov: Avtoref. dis. ... d-ra med. nauk. – SPb. – 2006. – 37 s.
    • Kondakova M. N. Allel'nyj polimorfizm gena HLA-DRB1* u podrostkov i ego rol' v vybore rezhima himioterapii tuberkuleza organov dyhanija / M. N. Kondakova, M. V. Pavlova, L. A. Skvorcova // Nauchn. trudy Vseros. nauchno-prakt. konf. –SPb. – 2006. – S. 274–277.
    • Novickij V. V., Osobennosti funkcional'noj aktivnosti limfocitov krovi u bol'nyh tuberkulezom legkih / V.V. Novickij, A.K. Strelis, O.I. Urazov i dr. // Immunologija. – 2006. No 2. – S. 76–79.
    • Sulejmanov S.Sh. Osobennosti funkcionirovanija sistemy biotransformacii ksenobiotikov v adaptivnyh reakcijah i patologii malochislennyh narodov Krajnego Severa: avtoref. dis. … d-ra med. nauk. – Volgograd. – 1997. – 47 s.
    • Shevchenko O.V. Vlijanie polimorfizmov gena NAT2 na metabolizm holesterola u bol'nyh arterial'noj gipertenziej / O.V. Shevchenko, E.N. Bychkov, A.A. Svistunov [i dr.] // Fundamental'nye issledovanija. – 2012. – № 7–1. – S. 219-223.
    • Bellamy R. Genetic susceptibility to tuberculosis in Africans: A genome-wide scan / R. Bellamy, N. Beyers, KPWJ. McAdam [et al.] // Proceedings of the National Academy of Sciences of the United States of America. - 2000, Vol. 97, P. 8005–8009.
    • Borlak J. M. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients / J. Borlak, S. M. Reamon-Buettner // BMC Medical Genetics. - 2006, Vol.7, 58 p.
    • Cooke G. S. Mapping of a Novel Susceptibility Locus Suggests a Role for MC3R and CTSZ in Human Tuberculosis / G.S. Cooke, S. J. Campbell, S, Bennett [et al.] // Am. J. Respir. Crit. Care Med. - 2008, Vol.178, P. 203–207.
    • Evans D.A.P. N-acetyltransferase / D.A.P. Evans // Pharm. Therap. – 1989. – № 42. – P. 157–234.
    • Huang Y.S. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury / Y.S. Huang // - Expert Opin. Drug Metab. Toxicol., Vol.3 - 2007, P. 1–8.
    • Jamieson S. E. Evidence for a cluster of genes on chromosome 17q11–q21 controlling susceptibility to tuberculosis and leprosy in Brazilians / S.E. Jamieson, E. N. Miller, G.F. Black [et al.] // Genes Immun. - 2004, Vol.5, P.46–57.
    • Leiro-Fernandez V. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians / V. Leiro-Fernandez, D. Valverde, R. Vázquez-Gallardo [et al.] // Int. J. Tuberc. Lung Dis., 15, -2011, R. 1403–1408.
    • Nebert D.W. Polymorphisms in drug metabolising enzymes: what is their clinical relevance and why do they exist? / D.W. Nebert // A.J.Hum.Genet. - 1997, Vol.60.- P.265-271.
    • NAT2Nomenclature [http://louisville.edu/medschool/pharmacology/NAT.html] webcite
    • Tuberculosis. Edited by: Christoph Lange and Giovanni Battista Migliori. European Respiratory Society Monograph, - 2012. - Vol. 58. - P.38-58.
    • Yamada S. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population / S. Yamada, M. Tang, K. Richardson, [et al.] // Pharmacogenomics, Vol. 10 - 2009, P. 1433–1445.
    Publication of the article «World of Medicine and Biology» №1(48), 2015 year, 043-046 pages, index UDK 616.24-002.5:615.28